Leaflet TEKTROTYD 20mcg kit for radiopharmaceutical preparations


Indicated for: diagnostic imaging

Route of administration: injectable

Substance: radiopharmaceuticals (contrast agent)

ATC: V09IA07 (Various | Tumour detection | Technetium (99mtc) compounds)

Radiopharmaceuticals are substances used in nuclear medicine for the diagnosis and treatment of various conditions. They contain radioactive isotopes that emit detectable radiation for imaging, such as positron emission tomography (PET) or scintigraphy.

Radiopharmaceuticals are administered intravenously, orally, or by inhalation, depending on the type of investigation or treatment. It is important for these substances to be handled and administered by qualified personnel to minimize radiation exposure.

Patients should be informed about potential risks, such as radiation exposure or allergic reactions. It is important to follow all instructions provided before and after the procedure.

Side effects are rare but may include allergic reactions or discomfort at the injection site. In very rare cases, complications related to radiation exposure may occur. Patients should be informed of these risks before use.

General data about TEKTROTYD 20mcg

  • Substance: radiopharmaceuticals
  • Date of last drug list: 01-05-2026
  • Commercial code: W63076001
  • Concentration: 20mcg
  • Pharmaceutical form: kit for radiopharmaceutical preparations
  • Quantity: 1
  • Product type: generic
  • Price: 2438.51 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: NARODOWE CENTRUM BADAN JADROWYCH - POLONIA
  • Holder: NARODOWE CENTRUM BADAN JADROWYCH - POLONIA
  • Number: 14135/2021/01
  • Shelf life: 1 year-after packaging for sale;after reconstitution-4 hours

Concentrations available for radiopharmaceuticals

  • 1mg
  • 20mcg